...is OrbiMed Advisors venture partner Jim Sullivan. Ocugen partners with CanSino on retinal gene therapy Ocugen Inc....
...3 group E member 3 BioCentury Staff AbbVie Inc. Allergan Inc. Simcere Pharmaceutical Group JW Pharmaceutical Corp. Q-State Biosciences Inc. CanSino Biologics Inc. Ocugen Inc. URC-102 The...

...form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc....
...own about 90% of the resulting company, which will trade on NASDAQ and be named Ocugen Inc....
...will own about 10%. The transaction is expected to close in late 2Q19 or 3Q19. Ocugen...

...Bing Li as CEO. He was managing director at Fosun International Ltd. (HKSE:656). Ophthalmology company Ocugen Inc....

...Dry Eye (SANDE) scores and conjunctival and corneal staining with lissamine green, compared with placebo. Ocugen...
...an upcoming meeting. The double-blind, U.S. trial enrolled about 90 patients with dry eye disease. Ocugen...
...a relatively selective adrenergic receptor alpha 2 (ADRA2) agonist, combined with loteprednol etabonate, a corticosteroid. Ocugen Inc....

...Ophthalmology company Ocugen Inc. (Malvern, Pa.) raised $7.5 million in a series B round led by Abdi...
...JSC Lancaster Group on June 15. Existing individual investors also participated. Ocugen Inc. , Malvern, Pa. Alex Himes Ocugen Inc....

...series A round from EB5 Life Sciences and former pharma executives. Ocugen Inc. , Aurora, Colo. Alicia Parker Ocugen Inc....

...The university granted Ocugen exclusive, worldwide rights to develop and commercialize OCU300 . The repurposed undisclosed...
...in a post hoc analysis of an exploratory observational study in ocular graft-versus-host disease (GvHD). Ocugen...
...data on safety and efficacy from scientific literature or from previously approved products. In 2017, Ocugen...

...and SFRS1-interacting protein ( PSIP1 ; LEDGF ; p75; LEDGF/p75 ) fragment 1-326, in 2015. Ocugen...
...worldwide rights from the University of Colorado to all assets related to LEDGF, including OCU100. Ocugen Inc....

...The university granted Ocugen exclusive, worldwide rights to assets related to PC4 and SFRS1-interacting protein...
...in development for wet age-related macular degeneration (AMD). The parties declined to disclose financial terms. Ocugen Inc....